Evidence map›Paper›PMID 28756482›Full record

ArticleCell biochemistry and biophysics2017

EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.

H Gustafsson, A Kale, A Dasu, A Lund, P-H Edqvist, K Roberg

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

H GustafssonDepartment of Radiology Norrköping and Department of Medical and Health Sciences (IMH), Linköping University, Linköping, Sweden. hakan.l.gustafsson@liu.se.ORCID http://orcid.org/0000-0001-6148-1053
A KaleDivision of Oto-Rhino-Laryngology and Head and Neck Surgery, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
A DasuDepartment of Medical and Health Sciences, Linköping University, Linköping, Sweden.ORCID http://orcid.org/0000-0001-8171-2541
A LundDepartment of Physics, Chemistry and Biology (IFM), Linköping University, Linköping, Sweden.
P-H EdqvistDepartment of Immunology, Genetics and Pathology and Science for Life Laboratory, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.
K RobergDivision of Oto-Rhino-Laryngology and Head and Neck Surgery, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
Linköping University · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite advances in therapy. The monoclonal antibody cetuximab (Erbitux

Indexed as

Electron Spin Resonance SpectroscopyOximetryAnimalsAntineoplastic Agents, ImmunologicalCarcinoma, Squamous CellCell Line, TumorCetuximabDisease Models, AnimalErbB ReceptorsFemaleGlucose Transporter Type 1Head and Neck NeoplasmsHumansHypoxiaHypoxia-Inducible Factor 1, alpha SubunitImmunohistochemistryAntineoplastic Agents, ImmunologicalCetuximabErbB ReceptorsGlucose Transporter Type 1Hypoxia-Inducible Factor 1, alpha SubunitKi-67 AntigenOxygenCetuximabEPR oximetryHead and neck cancerHypoxiaMetabolismTumour oxygen pressure

Identifiers

PMID28756482
PMCPMC5691101
OpenAlexW2741281360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.